Company Profile
Protara Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Protara Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Protara Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Protara Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Protara Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
TARA is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Protara's next big marker is still TARA-002 in non-muscle invasive bladder cancer. The 68 percent complete response rate at six months is the kind of data point that makes the ADVANCED-2 trial worth following, especially with enrollment on track in the BCG-unresponsive cohort.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
Source: Protara Therapeutics
- 02
- 03
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Source: Protara Therapeutics
- 04
- 05
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
Source: Protara Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.